The developing role of theranostics in NETs
Mené sur 226 patients atteints d'une tumeur neuroendocrine gastro-entéro-pancréatique bien différenciée de grade 2/3, de stade avancé et récemment diagnostiquée, cet essai randomisé de phase III évalue l'efficacité, du point de vue de la survie sans progression, et la toxicité de l'ajout du lutétium 177 DOTA-TATE à l'octréotide à action prolongée en traitement de première ligne
Neuroendocrine tumours (NETs) are categorised as rare tumours, but the incidence continues to increase. 1 Most commonly, these tumours arise within the gastrointestinal tract or pancreas and are collectively known as gastroenteropancreatic NETs. 1 These tumours are classified by WHO into grades according to mitotic index, differentiation status and Ki67 proliferative index, which translates into aggressiveness. 2 For patients with advanced disease, few treatment options exist but include somatostatin analogues, targeted therapy, chemotherapy, and peptide receptor radionuclide therapy (PRRT). 3 , 4 , 5 , 6 , 7 , 8 Furthermore, the change in the WHO grade 3 classification into well and poorly differentiated tumours makes the current optimal treatment for well differentiated grade 3 gastroenteropancreatic NETs undefined.